Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04910867 · ClinicalTrials.gov registry record · NA
APOL1 Genetic Testing Program for Living Donors
A NA study of Chronic Kidney Diseases and Kidney Transplantation, sponsored by Northwestern University.
- Active
- Registry status
- NA
- Development phase
- 206
- Enrollment target
- 2
- Study locations
NCT04910867: Active NA study of Chronic Kidney Diseases and Kidney Transplantation, sponsored by Northwestern University.
NCT04910867 is a NA study of Chronic Kidney Diseases and Kidney Transplantation that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 206 participants, below the 442-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04910867, a NA study of Chronic Kidney Diseases and Kidney Transplantation, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 206 participants
- Enrollment target
- 2
- Study locations
Study Summary
Living donor (LD) kidney transplantation is the optimal treatment for patients with end-stage kidney disease (ESKD). However, LDs take on a higher risk of future ESKD themselves. African American (AA) LDs have an even greater, 3.3-fold, risk of ESKD than white LDs post-donation. Because evidence suggests that Apolipoprotein L1 (APOL1) risk variants contribute to this greater risk, transplant nephrologists are increasingly using APOL1 testing to evaluate LD candidates of African ancestry. However, nephrologists do not consistently perform genetic counseling with LD candidates about APOL1 due to a lack of knowledge and skill in counseling about APOL1. Without proper counseling, APOL1 testing will magnify LD candidates' decisional conflict about donating, jeopardizing their informed consent. Given their elevated risk of ESRD post-donation, and AAs' widely-held cultural concerns about genetic testing, it is ethically critical to protect AA LD candidates' safety through APOL1 testing in a culturally competent manner to improve informed decisions about donating. No transplant programs have integrated APOL1 testing into LD evaluation in a culturally competent manner. Clinical "chatbots," mobile apps that use artificial intelligence to provide genetic information to patients and relieve constraints on clinicians' time, can improve informed treatment decisions and reduce decisional conflict. The chatbot "Gia," created by a medical genetics company, can be adapted to any condition. However, no chatbot on APOL1 is currently available. No counseling training programs are available for nephrologists to counsel AA LDs about APOL1 and donation in a culturally competent manner. Given the shortage of genetic counselors, increasing nephrologists' genetic literacy is critical to integrating genetic testing into practice. The objective of this study is to culturally adapt and evaluate the effectiveness of an APOL1 testing program for AA LDs at two transplant centers serving large AA
Primary Outcome
The Decisional Conflict Scale will measure donor candidates' perceived uncertainty in decision-making about donating and satisfaction with effective decision-making. Scores range from: 0-100 Higher scores reflect greater decisional conflict (a worse outcome).
Conditions Studied
Interventions
- BEHAVIORAL Components of Genetic Counseling
- DIAGNOSTIC_TEST APOL1 genetic testing
- OTHER EHR integration
Study Locations (2)
District of Columbia
- Medstar Georgetown Transplant Institute - Washington D.C.
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What the registry record for NCT04910867 still lists
NCT04910867 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, below the 442-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (53% lower).
The record links to 3 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 3 interventions - of which Components of Genetic Counseling is the first listed.
NCT04910867 reports a single indexed study location in District of Columbia, Illinois.
Frequently Asked Questions
What is clinical trial NCT04910867 about?
NCT04910867 is a clinical study titled "APOL1 Genetic Testing Program for Living Donors". Living donor (LD) kidney transplantation is the optimal treatment for patients with end-stage kidney disease (ESKD). However, LDs take on a higher risk of future ESKD themselves. African American (AA) LDs have an even greater, 3.3-fold, risk of ESKD than white LDs post-donation. Because evidence sug...
What is the current status of trial NCT04910867?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 206 participants. The study started on 2021-09-09. Estimated completion is 2026-03-31.
What conditions does trial NCT04910867 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases, Kidney Transplantation, Apolipoprotein L1.
What interventions are being tested in trial NCT04910867?
The interventions under investigation include: Components of Genetic Counseling (BEHAVIORAL), APOL1 genetic testing (DIAGNOSTIC_TEST), EHR integration (OTHER).
Who is sponsoring clinical trial NCT04910867?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04910867 being conducted?
This trial has 2 study locations across District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04910867's enrollment target sits among peer trials
206 26th of 73 higher than 48 of 73 other Chronic Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Mindfulness in Chronic Kidney Disease
RECRUITING · NA
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
-
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
RECRUITING · NA
-
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
RECRUITING · NA
-
Handgrip Exercise Training and CKD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI